[Not Available].
Fiche publication
Date publication
novembre 2022
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi
Tous les auteurs :
Delaye M, Assenat E, Boleslawski E, Camus M, Edeline J, Henriques J, Herrero A, Lièvre A, Malka D, Turpin A, Vernerey D, Neuzillet C
Lien Pubmed
Résumé
Overview of biliary tract cancer management practices in France: results of the ACABi national survey INTRODUCTION: Biliary tract cancers (BTC) are rare. Their management has evolved in recent years. ACABi conducted a survey on the management practices of CVB in France. METHODS: A questionnaire was developed by a multidisciplinary team and distributed (June-July 2021) by the French digestive oncology societies. The data were analyzed according to the type of practice center (group A: university hospital or cancer comprehensive center, group B: general hospital or private hospital) RESULTS: 172 physicians (hepato-gastroenterologists: 58.0%, oncologists: 19.5% and surgeons: 18.3%), representing all French regions, responded. Access to echo-endoscopy and endoscopic retrograde cholangio-pancreatography was identical between the groups (> 80%), unlike cholangioscopy (group A: 82.9%, group B: 63.6%). In the adjuvant setting, capecitabine was proposed in the majority (> 65%). For non-operable tumors, the most commonly used first-line chemotherapy was cisplatin/gemcitabine (CISGEM, 66.3%). In 38.5% of cases, it was not performed in the day hospital and only 13.6% proposed a break after a fixed number of courses. The most commonly used second-line treatment was 5FU/oxaliplatin (FOLFOX, 52.3%). Molecular profiling was performed in more than half of the patients for 41.1% of respondents in group A and 18.8% in group B. DISCUSSION: This survey shows the application of therapeutic standards but also certain practices diverging from the recommendations as well as disparities between centers.
Mots clés
Biliary tract cancers, CISGEM, Diagnostic moléculaire, Molecular profiling, Practice assessment, Tumeurs des voies, biliaires, des pratiques, Évaluation
Référence
Bull Cancer. 2022 11;109(11S):11S3-11S10